Literature DB >> 23080298

Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice.

Maria J Perugorria1, Lindsay B Murphy, Nicola Fullard, Jayashree B Chakraborty, Dimitra Vyrla, Caroline L Wilson, Fiona Oakley, Jelena Mann, Derek A Mann.   

Abstract

UNLABELLED: Toll-like receptors (TLRs) function as key regulators of liver fibrosis and are able to modulate the fibrogenic actions of nonparenchymal liver cells. The fibrogenic signaling events downstream of TLRs on Kupffer cells (KCs) and hepatic stellate cells (HSCs) are poorly defined. Here, we describe the MAP3K tumor progression locus 2 (Tpl2) as being important for the activation of extracellular regulated kinase (ERK) signaling in KCs and HSCs responding to stimulation of TLR4 and TLR9. KCs lacking Tpl2 display defects with TLR induction of cytokines interleukin (IL)-1β, IL-10, and IL-23. tpl2(-/-) HSCs were unable to increase expression of fibrogenic genes IL-1β and tissue inhibitor of metalloproteinase 1 (TIMP-1), with the latter being the result of defective stimulation of TIMP-1 promoter activity by TLRs. To determine the in vivo relevance of Tpl2 signaling in liver fibrosis, we compared the fibrogenic responses of wild-type (WT) and tpl2(-/-) mice in three distinct models of chronic liver injury. In the carbon tetrachloride and methionine-choline-deficient diet models, we observed a significant reduction in fibrosis in mice lacking Tpl2, compared to WT controls. However, in the bile duct ligation model, there was no effect of tpl2 deletion, which may reflect a lesser role for HSCs in wounding response to biliary injury.
CONCLUSION: We conclude that Tpl2 is an important signal transducer for TLR activation of gene expression in KCs and HSCs by the ERK pathway and that suppression of its catalytic activity may be a route toward suppressing fibrosis caused by hepatocellular injuries. (HEPATOLOGY 2013).
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23080298     DOI: 10.1002/hep.26108

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Deletion of tumor progression locus 2 attenuates alcohol-induced hepatic inflammation.

Authors:  Camilla P Stice; Sajid Hussain; Chun Liu; Lynne M Ausman; Xiang-Dong Wang; Andrew S Greenberg
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

2.  The c-Rel subunit of NF-κB regulates epidermal homeostasis and promotes skin fibrosis in mice.

Authors:  Nicola Fullard; Anna Moles; Steven O'Reilly; Jacob M van Laar; David Faini; Julie Diboll; Nick J Reynolds; Derek A Mann; Julia Reichelt; Fiona Oakley
Journal:  Am J Pathol       Date:  2013-04-04       Impact factor: 4.307

3.  Sterile inflammation in acetaminophen-induced liver injury is mediated by Cot/tpl2.

Authors:  Carlos Sanz-Garcia; Gemma Ferrer-Mayorga; Águeda González-Rodríguez; Angela M Valverde; Antonio Martín-Duce; Juan P Velasco-Martín; Javier Regadera; Margarita Fernández; Susana Alemany
Journal:  J Biol Chem       Date:  2013-04-09       Impact factor: 5.157

4.  The role of tumor progression locus 2 protein kinase in glial inflammatory response.

Authors:  Joshua Hirschhorn; Sangeeta Mohanty; Narayan R Bhat
Journal:  J Neurochem       Date:  2013-11-21       Impact factor: 5.372

5.  A Human Anti-Toll Like Receptor 4 Fab Fragment Inhibits Lipopolysaccharide-Induced Pro-Inflammatory Cytokines Production in Macrophages.

Authors:  Maorong Wang; Wenkai Zheng; Xuhui Zhu; Jing Xu; Binggang Cai; Yiqing Zhang; Feng Zheng; Linfu Zhou; Zhiguo Yang; Xin Zhang; Changjun Wang; Shinan Nie; Jin Zhu
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

6.  TPL-2 Regulates Macrophage Lipid Metabolism and M2 Differentiation to Control TH2-Mediated Immunopathology.

Authors:  Yashaswini Kannan; Jimena Perez-Lloret; Yanda Li; Lewis J Entwistle; Hania Khoury; Stamatia Papoutsopoulou; Radma Mahmood; Nuha R Mansour; Stanley Ching-Cheng Huang; Edward J Pearce; Luiz Pedro S de Carvalho; Steven C Ley; Mark S Wilson
Journal:  PLoS Pathog       Date:  2016-08-03       Impact factor: 6.823

Review 7.  Cytoglobin as a Marker of Hepatic Stellate Cell-derived Myofibroblasts.

Authors:  Norifumi Kawada
Journal:  Front Physiol       Date:  2015-11-13       Impact factor: 4.566

8.  The transcriptomic response of rat hepatic stellate cells to endotoxin: implications for hepatic inflammation and immune regulation.

Authors:  Stephen A K Harvey; Anil Dangi; Ashish Tandon; Chandrashekhar R Gandhi
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

9.  Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C.

Authors:  Akihito Tsubota; Kaoru Mogushi; Hideki Aizaki; Ken Miyaguchi; Keisuke Nagatsuma; Hiroshi Matsudaira; Tatsuya Kushida; Tomomi Furihata; Hiroshi Tanaka; Tomokazu Matsuura
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

10.  A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo.

Authors:  Saimir Luli; Daniela Di Paolo; Patrizia Perri; Chiara Brignole; Stephen J Hill; Helen Brown; Jack Leslie; H L Marshall; Matthew C Wright; Derek A Mann; Mirco Ponzoni; Fiona Oakley
Journal:  J Hepatol       Date:  2016-04-09       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.